No Data
No Data
Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing
Benjamin L Palleiko, Director, CEO, on May 17, 2024, sold 21,959 shares in Kalvista Pharmaceuticals (KALV) for $258,337. Following the Form 4 filing with the SEC, Palleiko has control over a total of
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its
When Will KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Breakeven?
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. KalVista Pharmaceuticals, Inc., a clinic
KalVista Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
KalVista Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on KalVista Pharma, Lowers Price Target to $20
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)
No Data